123 related articles for article (PubMed ID: 8757508)
1. Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.
Dedera DA; Urashima M; Chauhan D; LeBrun DP; Bronson RT; Anderson KC
Br J Haematol; 1996 Jul; 94(1):53-61. PubMed ID: 8757508
[TBL] [Abstract][Full Text] [Related]
2. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
[TBL] [Abstract][Full Text] [Related]
3. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
4. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
Rico-Vargas SA; Potter M; Osmond DG
J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
[TBL] [Abstract][Full Text] [Related]
5. The role of interleukin 6 in plasmacytomagenesis.
Hirano T; Suematsu S; Matsusaka T; Matsuda T; Kishimoto T
Ciba Found Symp; 1992; 167():188-96; discussion 196-200. PubMed ID: 1425013
[TBL] [Abstract][Full Text] [Related]
6. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoma arising in giant lymph node hyperplasia.
Schlosnagle DC; Chan WC; Hargreaves HK; Nolting SF; Brynes RK
Am J Clin Pathol; 1982 Oct; 78(4):541-4. PubMed ID: 7137088
[TBL] [Abstract][Full Text] [Related]
8. Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas.
Armstrong MY; Ebenstein P; Konigsberg WH; Richards FF
Proc Natl Acad Sci U S A; 1978 Sep; 75(9):4549-52. PubMed ID: 212759
[TBL] [Abstract][Full Text] [Related]
9. The enhancement of growth of a syngeneic plasmacytoma in BALB/c mice by pristane priming is not due to immunosuppressive effects on antibody-forming cell or mitogen-responsive splenocytes.
Ruiz-Bravo A; Perez M; Jimenez-Valera M
Immunol Lett; 1995 Jan; 44(1):41-4. PubMed ID: 7721342
[TBL] [Abstract][Full Text] [Related]
10. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.
Zhang SL; DuBois W; Ramsay ES; Bliskovski V; Morse HC; Taddesse-Heath L; Vass WC; DePinho RA; Mock BA
Mol Cell Biol; 2001 Jan; 21(1):310-8. PubMed ID: 11113205
[TBL] [Abstract][Full Text] [Related]
11. Caspase-1 is required for maintenance of marginal zone B cells in pristane-induced lupus.
Morse MD; Clark KL; Cascalho M; Kahlenberg JM
Lupus; 2016 Jan; 25(1):81-7. PubMed ID: 26405027
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
[TBL] [Abstract][Full Text] [Related]
13. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice.
Davidson WF; Roths JB; Holmes KL; Rudikoff E; Morse HC
J Immunol; 1984 Aug; 133(2):1048-56. PubMed ID: 6610701
[TBL] [Abstract][Full Text] [Related]
15. Different migration patterns of antigen-presenting cells correlate with Th1/Th2-type responses in mice.
Morikawa Y; Tohya K; Ishida H; Matsuura N; Kakudo K
Immunology; 1995 Aug; 85(4):575-81. PubMed ID: 7558152
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.
Schirmacher P; Peters M; Ciliberto G; Blessing M; Lotz J; Meyer zum Büschenfelde KH; Rose-John S
Am J Pathol; 1998 Aug; 153(2):639-48. PubMed ID: 9708822
[TBL] [Abstract][Full Text] [Related]
17. v-abl does not abolish IL-6 requirement by murine plasmacytoma cells.
Sugiyama H; Wiener F; Babonits M; Silva S; Hirano T; Kishimoto T; Klein G
Int J Cancer; 1991 May; 48(2):234-8. PubMed ID: 2019468
[TBL] [Abstract][Full Text] [Related]
18. Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane.
Janz S; Gawrisch K; Lester DS
Cancer Res; 1995 Feb; 55(3):518-24. PubMed ID: 7834620
[TBL] [Abstract][Full Text] [Related]
19. IL-6 transgenic mouse model for extraosseous plasmacytoma.
Kovalchuk AL; Kim JS; Park SS; Coleman AE; Ward JM; Morse HC; Kishimoto T; Potter M; Janz S
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1509-14. PubMed ID: 11805288
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of pristane-induced peritoneal plasmacytoma formation.
Potter M; Kutkat L
Curr Top Microbiol Immunol; 1999; 246():351-61; discussion 361-2. PubMed ID: 10396075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
